Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million

Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million GlobeNewswire November 13, 2025 Management Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025 Ramping Business Lines Expected to Achieve Positive Operating Cash Flows […]

First Watch Restaurant Group, Inc. to Participate at the Stephens Annual Investment Conference on November 18-19, 2025

(NASDAQ:FWRG), BRADENTON, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc., (Nasdaq: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced that it will attend the Stephens Annual Investment Conference to meet with institutional investors and host a fireside chat on Tuesday, November

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY(R) Cell-Impermeable Endoprosthesis

(NASDAQ:MMSI), SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY(R) Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

(NASDAQ:BCAB), Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval Company is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction

Profound Medical Reports Strong Third Quarter 2025 Financial Results

Profound Medical Reports Strong Third Quarter 2025 Financial Results GlobeNewswire November 13, 2025 TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the

BioSyent Schedules Q3 and YTD 2025 Earnings Release for November 20, 2025

(TSX-V:RX), MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and nine months ended September 30, 2025 on Thursday, November 20, 2025 after market hours. A presentation on the Company's third quarter and year-to-date 2025 results by Rene

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

(NasdaqGM:RNAC), 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient

Shimmick Corporation Announces Third Quarter 2025 Results

Shimmick Corporation Announces Third Quarter 2025 Results GlobeNewswire November 13, 2025 IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the third quarter ended October 3, 2025. Third Quarter 2025 and Recent Highlights

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

(NASDAQ:ICU), Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance Registry New clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollment Strengthened the balance sheet, raising $12.4 million to

Hudson Technologies Appoints Kenneth Gaglione as Chairman of the Board, President and Chief Executive Officer

Hudson Technologies Appoints Kenneth Gaglione as Chairman of the Board, President and Chief Executive Officer GlobeNewswire November 13, 2025 WOODCLIFF LAKE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) (the “Company”) today announced that its Board of Directors has appointed Kenneth Gaglione as Chairman of the Board, President and Chief Executive

Scroll to Top